Tag: Intravacc
Intravacc launches phase I clinical trial of Avacc 10, an intranasal...
Randomized, double blinded, placebo-controlled trial. Evaluation of two doses in 36 volunteers. Mid-term data expected by end Q1 2023
CEPI commits US$4.8 million to Intravacc for developing intranasal Betacoronavirus vaccine
Under the terms of the funding agreement, Intravacc has committed to achieving equitable access to the outputs of this project, in line with CEPI’s Equitable Access Policy
Intravacc releases more data on its intranasal SARS-CoV-2 vaccine candidate
Additional pre-clinical data of Avacc 10®indicate reduction in upper respiratory tract viral load and cross neutralization of variants of concern